129788654670937500_52International private equity giant KKR paid $ 65 million investment China cord blood bank mobile phone free www.cnfol.com April 14, 2012, the Shanghai Securities News view comments ⊙ reporter Shi Beibei 0 edit Yang Xiaokun world's leading private equity investment company Kohlberg Kravis Roberts Co.L.P. (Hereinafter referred toUs $. According to sources close to the deal, the investment in convertible bonds, if you have them converted to equity, KKR in umbilical cord blood banking conglomerate's stake in China amounted to 23.8%.Said the investment to investment in more than 10 times earnings, but KKR is more important companies ' cash flow, management team, business development, and other factors. KKR said global partner Julian Wolhardt, umbilical cord blood bank in China Enterprise Group has worked with over the last 10 years of outstanding professional management team. In addition, umbilical cord blood bank in ChinaBusiness platform will be accompanied by the expansion of the field of application of umbilical cord blood stem cells and continuously improve. After the sum of money into, will be mainly used to support business expansion and the development of the umbilical cord blood bank in China. Umbilical cord blood banking conglomerate in China was first made in China practice of umbilical cord blood bank operators license in 2009, listed on the New York Stock Exchange, in mainland China cord blood bankNetworks cover a wide range of services. Contains a large number of stem cells in umbilical cord blood, on the premise of safe-keeping, with clinical requirements for critical illness in the future or in the treatment of treatment. Umbilical cord blood stem cell treatment is gradually expanding the scope of has been covered as much as 80 diseases, including well-known leukemia, lymphoma, and Eastern Mediterranean anemia, congenital immune failure andImmune diseases.
According to people close to the deal said above, KKR investment was its first single investment in China's medical services industry, industry growing at an annual rate of 30% of umbilical cord blood contains a huge development space, and KKR's investment experience in the medical industry in the international market
tera power leveling, and can be applied to the market in mainland China. It is understood, KKRGrowth Fund of us $ 1 billion, was completed last year of fundraising, is in the investment period. Founded in 1976, KKR
tera power leveling, as at December 31, 2011, KKR assets under management amounted to 59 billion dollars, with 14 offices worldwide
tera gold, including Beijing, through its investment fund and managed accounts for different categories of assets.
Others:
No comments:
Post a Comment